Corcept Therapeutics (CORT) Price & Analysis

Compare

1,061 Followers

CORT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$33.34 - $117.33

Previous CloseN/A

Volume78.39K

Average Volume (3M)830.71K

Market Cap

$7.40B

Enterprise Value$8.51B

Total Cash (Recent Filing)$342.23M

Total Debt (Recent Filing)$6.61M

Price to Earnings (P/E)62.6

Beta0.38

Next Earnings

Oct 29, 2025

EPS Estimate

0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding105,371,730

10 Day Avg. Volume660,270

30 Day Avg. Volume830,709

Financial Highlights & Ratios

PEG Ratio1.15

Price to Book (P/B)7.65

Price to Sales (P/S)7.71

P/FCF Ratio26.55

Enterprise Value/Market Cap1.15

Enterprise Value/Revenue11.88

Enterprise Value/Gross Profit12.08

Enterprise Value/Ebitda81.93

Forecast

1Y Price Target

$123.20

Price Target Upside73.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPositive results from the pivotal ROSELLA study with relacorilant in ovarian cancer give confidence in its potential for a new indication.

Regulatory ProgressAn NDA submission for relacorilant in Cushing’s has been accepted for filing by the FDA, indicating strong regulatory progress.

Bears Say

Legal UncertaintyThe appellate court decision on Korlym IP is expected to be a stock-moving event, which adds uncertainty to the stock.

Supply Chain IssuesDemand continues to outstrip supply for Korlym, and insufficiency at the company's specialty pharmacy vendor has caused revenue to fall short of estimates.

Corcept Therapeutics News

Corcept Therapeutics price target lowered to $121 from $131 at Piper Sandler

Piper Sandler analyst David Amsellem lowered the firm’s price target on Corcept Therapeutics (CORT) to $121 from $131,...

21d ago

CORT

Corcept Therapeutics price target lowered to $137 from $142 at Canaccord

Canaccord analyst Edward Nash lowered the firm’s price target on Corcept Therapeutics (CORT) to $137 from $142 and...

21d ago

CORT

Corcept Therapeutics reports Q2 EPS 29c, consensus 19c

Reports Q2 revenue $194.4M, consensus $199.4M. “The second quarter marked another period of robust growth in our hypercortisolism...

22d ago

CORT

Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting a Phase 1...

8d ago

CORT

Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics, retaining the price target of...

8d ago

CORT

Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting a study titled...

15d ago

CORT

Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is currently recruiting participants for...

15d ago

CORT

Corcept Therapeutics’ Earnings Call: Growth Amid Challenges

Corcept Therapeutics (($CORT)) has held its Q2 earnings call. Read on for the main highlights of the call....

21d ago

CORT

Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches

Analyst Swayampakula Ramakanth of H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics, retaining the price target of...

21d ago

CORT

Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses

Corcept Therapeutics ( ($CORT) ) has released its Q2 earnings. Here is a breakdown of the information Corcept...

22d ago

CORT

Corcept Therapeutics Reports Q2 2025 Financial Results

An update from Corcept Therapeutics ( ($CORT) ) is now available. On July 31, 2025, Corcept Therapeutics announced...

22d ago

CORT

Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome

Corcept Therapeutics (($CORT)) announced an update on their ongoing clinical study. Corcept Therapeutics is conducting an extension study...

23d ago

CORT

Is CORT a Buy, Before Earnings?

Corcept Therapeutics (CORT) is scheduled to report 2nd quarter earnings on 07/31/2025, after the market closes. Regarding Q2...

24d ago

CORT

Piper Sandler pharmaceuticals analyst holds analyst/industry conference call

Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)’ Relacorilant in ovarian cancer on an Analyst/Industry conference...

1M ago

CORT

CORT FAQ

What was Corcept Therapeutics Inc.’s price range in the past 12 months?

Corcept Therapeutics Inc. lowest stock price was $33.34 and its highest was $117.33 in the past 12 months.

What is Corcept Therapeutics Inc.’s market cap?

Corcept Therapeutics Inc.’s market cap is $7.40B.

When is Corcept Therapeutics Inc.’s upcoming earnings report date?

Corcept Therapeutics Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 68 days.

How were Corcept Therapeutics Inc.’s earnings last quarter?

Corcept Therapeutics Inc. released its earnings results on Jul 31, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.188 by $0.102.

Is Corcept Therapeutics Inc. overvalued?

According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corcept Therapeutics Inc. pay dividends?

Corcept Therapeutics Inc. does not currently pay dividends.

What is Corcept Therapeutics Inc.’s EPS estimate?

Corcept Therapeutics Inc.’s EPS estimate is 0.17.

How many shares outstanding does Corcept Therapeutics Inc. have?

Corcept Therapeutics Inc. has 105,371,730 shares outstanding.

What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?

Corcept Therapeutics Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.188. Following the earnings report the stock price went up 2.724%.

Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?

Currently, no hedge funds are holding shares in CORT

Corcept Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

21.42%

Trailing 12-Months

Asset Growth

12.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corcept Therapeutics Inc.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics (CORT) Earnings & Revenues

Historic Earnings Reports

CORT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth, significant increases in prescriptions and market expansion, and successful clinical trial results. However, the call also noted challenges, such as a slight decline in net income, pharmacy capacity issues affecting revenue, and ongoing patent litigation. Despite these challenges, the overall sentiment leans positive due to promising trial results and strategic expansions.View all CORT earnings summaries

CORT Stock 12 Month Forecast

Average Price Target

$123.20

▲(73.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","62":"$62","90":"$90","118":"$118","146":"$146"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$123.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$78.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,62,90,118,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,74.84615384615384,80.6923076923077,86.53846153846153,92.38461538461539,98.23076923076923,104.07692307692307,109.92307692307692,115.76923076923077,121.61538461538461,127.46153846153845,133.30769230769232,139.15384615384613,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,73.16923076923077,77.33846153846154,81.50769230769231,85.67692307692307,89.84615384615384,94.01538461538462,98.18461538461538,102.35384615384615,106.52307692307693,110.6923076923077,114.86153846153846,119.03076923076924,{"y":123.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69,69.6923076923077,70.38461538461539,71.07692307692308,71.76923076923077,72.46153846153847,73.15384615384616,73.84615384615384,74.53846153846153,75.23076923076923,75.92307692307692,76.61538461538461,77.3076923076923,{"y":78,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >